Categories Uncategorized

UK Study Shows Dementia Risk Doubles for People with More Than One Chronic Disease

Dementia is a debilitating condition that affects individuals in their old age. The disease impacts around 57 million people globally, with experts predicting that by 2050, about 153 million individuals will have developed dementia.

To compound matters even more, a new study has found that the risk of a middle-aged individual developing dementia heightens significantly, especially if they suffer from two or more chronic health issues in middle age. This is known as multimorbidity, which is the presence of two or more chronic diseases from a list of 13 diseases, including cancer, arthritis, liver disease, depression, stroke, heart failure, diabetes and high blood pressure.

Dementia has no cure because it usually results from a variety of diseases, including frontotemporal dementia, Alzheimer’s disease and dementia with Lewy bodies. Over the past few years, studies have found evidence showing that most individuals living with dementia also suffer from multiple conditions, such as high blood pressure, heart disease, heart failure, diabetes, and liver disease.

However, few studies have looked into whether developing these indications at an earlier age grew the risk of developing dementia in old age. Researchers from the University of Paris and University College London sought to fill this knowledge gap. For their study, the researchers assessed the long-term relationship between developing dementia and contracting these conditions when an individual is aged 55, 60, 65 and 70.

They used data collected from more than 10,000 individuals who took part in the Whitehall II study between 1985 and 1988. All the individuals who participated in the study were between 35 and 55 years of age and hadn’t been diagnosed with dementia. This particular study looked at how biological, social and behavioral factors affected long-term health.

The researchers discovered that individuals who had multimorbidity before they hit 50 had a greater risk of developing dementia in comparison to those who developed these chronic conditions later in life. They also found that an individual’s risk of developing dementia grew by 18% for every five years they had multimorbidity before age 70. In addition, they discovered that individuals aged 70 with no chronic conditions had a significantly lower risk of dementia.

In their conclusion, the researchers noted that after adjusting for factors such as lifestyle, diet and socioeconomic status, the presence of two or more chronic conditions in an individual by age 55 increased the risk of developing dementia by more than two times.

The study’s findings were reported in the “British Medical Journal.”

Managing a patient’s chronic illnesses, such as diabetes, and using available interventions such as the medical technology tools developed by Nemaura Medical Inc. (NASDAQ: MNRD) could potentially have beneficial effects upon keeping the risk of dementia onset lower.

NOTE TO INVESTORS: The latest news and updates relating to Nemaura Medical Inc. (NASDAQ: NMRD) are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat

A recent report from India is a stark reminder of ricin’s accessibility and the pressing…

4 hours ago

Chronic Inflammation Could Be the Missing Key to Understanding Long Covid

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human…

1 day ago

Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology

Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has…

2 days ago

Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment

A new study done in India has produced results that bring into question the longstanding assumption that…

3 days ago

Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics

Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”)…

4 days ago

Study Highlights Increasing Cases of Breast Cancer in Younger Women

A study that involved an analysis of patient records in New York has discovered that…

1 week ago